Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.66 USD
Change Today +1.08 / 1.70%
Volume 739.1K
PRXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

parexel international corp (PRXL) Snapshot

Open
$64.00
Previous Close
$63.58
Day High
$65.14
Day Low
$63.57
52 Week High
04/10/15 - $71.42
52 Week Low
05/5/14 - $43.65
Market Cap
3.6B
Average Volume 10 Days
728.1K
EPS TTM
$2.73
Shares Outstanding
55.2M
EX-Date
--
P/E TM
23.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for PAREXEL INTERNATIONAL CORP (PRXL)

Related News

No related news articles were found.

parexel international corp (PRXL) Related Businessweek News

No Related Businessweek News Found

parexel international corp (PRXL) Details

PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance, and good manufacturing practice compliance consulting; and market development, product development, commercialization, and targeted communications services in support of product launch. The PI segment offers information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, regulatory information management solutions, platform solutions, clinical trial management system solutions, electronic data capture systems, Web-based portals, systems integration, electronic patient reported outcomes, and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

15,560 Employees
Last Reported Date: 08/20/14
Founded in 1983

parexel international corp (PRXL) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $883.3K
President and Chief Operating Officer
Total Annual Compensation: $570.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $691.5K
Senior Vice President of Clinical Research Se...
Total Annual Compensation: $496.7K
Executive Vice President
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

parexel international corp (PRXL) Key Developments

PAREXEL International Corporation Reports Consolidated Unaudited Financial Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Fourth Quarter and Full Year of Fiscal 2015

PAREXEL International Corporation reported consolidated unaudited financial results for the third quarter and nine months ended March 31, 2015. For the three months ended March 31, 2015 PAREXEL's consolidated service revenue increased by 2.0% to $502.0 million compared with $492.4 million in the prior year period. Revenue grew 5.1% on a constant currency basis, excluding the negative impact of foreign currency exchange rate movements of $15.4 million. Operating income as reported under Generally Accepted Accounting Principles (GAAP) totaled $54.2 million, or 10.8% of service revenue, in the third quarter of fiscal year 2015, as compared with $52.2 million, or 10.6% of service revenue, in the comparable quarter of the prior year. GAAP net income for the quarter totaled $37.7 million, or $0.68 per diluted share, compared with GAAP net income of $34.7 million, or $0.60 per diluted share for the quarter ended March 31, 2014. GAAP diluted earnings per share grew 13.3% year-over-year. Adjusted operating income in the third quarter of Fiscal Year 2015 was $54.1 million, or 10.8% of service revenue. Adjusted operating income in the third quarter of Fiscal Year 2014 was $53.2 million, or 10.8% of service revenue. Adjusted net income was $36.9 million, or $0.66 per diluted share in the quarter ended March 31, 2015, and was $32.3 million, or $0.56 per diluted share in the quarter ended March 31, 2014. Adjusted diluted earnings per share grew 17.9% year-over-year. Income from operations was $54.229 million against $52.171 million a year ago. Income before income taxes was $53.723 million against $49.807 million a year ago. Operational cash flow for the quarter was breakeven, driven by an increase of DSO to 38 days, which bounced back from an exceptionally low level in its December quarter. CapEx for the quarter was $22 million, in line with plans. Free cash flow for the March quarter was an outflow of approximately $22 million. Net debt came in at approximately $99 million, up sequentially as it used part of its revolving credit lines to fund higher working capital needs in the quarter. For the nine months ended March 31, 2015, consolidated service revenue was $1.493 billion versus $1.429 billion in the prior year period, an increase of 4.5%. GAAP operating income for the current nine-month period was $160.6 million, or 10.8% of service revenue, compared with GAAP operating income of $140.7 million, or 9.8% of service revenue in the prior year period. GAAP net income for the nine months ended March 31, 2015 was $113.6 million, or $2.04 per diluted share, compared with GAAP net income of $89.0 million, or $1.55 per diluted share, in the prior year period. GAAP diluted earnings per share grew 31.6% year-over-year. Adjusted operating income was $159.9 million or 10.7% of consolidated service revenue for the nine months ended on March 31, 2015, compared with $142.9 million or 10.0% of consolidated service revenue for the nine months ended on March 31, 2014. Adjusted net income for the nine months ended March 31, 2015 was $111.6 million, or $2.00 per diluted share, compared with $87.3 million or $1.52 per diluted share in the comparable prior year nine month period. Adjusted diluted earnings per share grew 31.6% year-over-year. Income from operations was $160.593 million against $140.716 million a year ago. Income before income taxes was $162.795 million against $131.680 million a year ago. The company provided earnings guidance for the fourth quarter and full year of fiscal 2015. For the quarter, the company expects revenues to be in the range of $520 million- $540 million, GAAP EPS was $0.65 - $0.81. For the year, the company expects revenues to be in the range of $2.012 billion- $2.032 billion, GAAP EPS was $2.68 - $2.86 per share, non-GAAP EPS was $2.65 - $2.83 per share.

PAREXEL International Corporation Launches LIQUENT InSight 6.0. Regulatory Information Management Platform

PAREXEL International Corporation announced that it has introduced the latest version of its Regulatory Information Management platform: LIQUENT InSight 6.0. The LIQUENT InSight platform supports the entire regulatory product lifecycle, from early planning of registration targets through product retirement, with robust submission planning, publishing, viewing and registration management capabilities. Enhancements to the LIQUENT InSight platform include: Business Intelligence: added robust analytics to enhance reporting capabilities; Usability: simplified interface designed by usability experts provide an intuitive experience to all levels of InSight users; Compliance: updated data model and architecture helps to ensure processes, output and work product compliance with standards such as XEVMPD and the upcoming IDMP mandate; and Interoperability: revamped interoperability web services features that help systems interact and communicate with each other.

PAREXEL International Corporation to Report Q3, 2015 Results on Apr 29, 2015

PAREXEL International Corporation announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Apr 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRXL:US $64.66 USD +1.08

PRXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $70.62 USD +1.46
GFK SE €34.06 EUR -0.93
ICON PLC $65.71 USD +1.37
PRA Health Sciences Inc $28.77 USD +0.29
WuXi PharmaTech Cayman Inc $45.18 USD +2.01
View Industry Companies
 

Industry Analysis

PRXL

Industry Average

Valuation PRXL Industry Range
Price/Earnings 23.6x
Price/Sales 1.8x
Price/Book -- Not Meaningful
Price/Cash Flow 14.9x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAREXEL INTERNATIONAL CORP, please visit www.parexel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.